Drug General Information
Drug ID	D0L7TA
Former ID	DIB013226
Drug Name	MIN-101
Indication	Schizophrenia [ICD9: 295; ICD10:F20]		Phase 1	[524902]
Company	Minerva neurosciences
Structure		Download 2D MOL 3D MOL
Target and Pathway
Target(s)	5-hydroxytryptamine 2A receptor	Target Info	Antagonist	[526792]
KEGG Pathway	Calcium signaling pathway
	Neuroactive ligand-receptor interaction
	Gap junction
	Serotonergic synapse
	Inflammatory mediator regulation of TRP channels
PANTHER Pathway	5HT2 type receptor mediated signaling pathway
Reactome	Serotonin receptors
	G alpha (q) signalling events
WikiPathways	Serotonin Receptor 2 and STAT3 Signaling
	Serotonin Receptor 2 and ELK-SRF/GATA4 signaling
	SIDS Susceptibility Pathways
	Monoamine GPCRs
	GPCRs, Class A Rhodopsin-like
	Gastrin-CREB signalling pathway via PKC and MAPK
	GPCR ligand binding
	GPCR downstream signaling
	GPCRs, Other
References
Ref 524902	ClinicalTrials.gov (NCT02232529) Pharmacokinetic Study of MIN-101 in Healthy Subjects. U.S. National Institutes of Health.
Ref 526792	Pharmacological profile of the new potent neuroleptic ocaperidone (R 79,598). J Pharmacol Exp Ther. 1992 Jan;260(1):146-59.

If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.